Evidence map›Paper›PMID 31240472›Full record

Trial reportAnnals of hematology2019

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Ivan Spicka, Enrique M Ocio, Heather E Oakervee, Richard Greil, Raymond H Banh, Shang-Yi Huang, James M D'Rozario, Meletios A Dimopoulos, Sara Martínez, Sonia Extremera and 11 more

Open access · hybridAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Novel molecules as the emerging trends in cancer treatment: an update.Medical oncology (Northwood, London, England) · 2022
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 18 institutions in 11 countries.

Ivan SpickaDepartment of Medicine, Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic.
Enrique M OcioDepartment of Hematology, University Hospital Marqués de Valdecilla/IDIVAL, University of Cantabria, Santander, Spain.
Heather E OakerveeDepartment of Haemato-Oncology, St Bartholomew's Cancer Centre, Barts Health NHS Trust, London, UK.
Richard Greil3rd Medical Department, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute, Cancer Cluster Salzburg, Salzburg, Austria.
Raymond H BanhDepartment of Clinical Haematology, Mater Health Services, Brisbane, Australia.
Shang-Yi HuangDepartment of Medicine, National Taiwan University Hospital, Taipei, Taiwan.
James M D'RozarioDepartment of Hematology, Canberra Hospital and Health Service, Canberra, Australia.
Meletios A DimopoulosDepartment of Clinical Therapeutics, Alexandra General Hospital, Athens, Greece.
Sara MartínezClinical R&D, Pharma Mar, Colmenar Viejo, Madrid, Spain.
Sonia ExtremeraClinical R&D, Pharma Mar, Colmenar Viejo, Madrid, Spain.
Carmen KahattClinical R&D, Pharma Mar, Colmenar Viejo, Madrid, Spain.
Vicente AlfaroClinical R&D, Pharma Mar, Colmenar Viejo, Madrid, Spain.
Angelo M CarellaDepartment of Hematology, IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy.
Nathalie MeulemanDepartment of Hematology, Institut Jules Bordet (ULB), Brussels, Belgium.
Roman HájekDepartment of Hematology-Oncology, Faculty of Medicine, University Hospital Ostrava, Ostrava, Czech Republic.
Argiris SymeonidisHematology Division, Department of Internal Medicine, University of Patras Medical School, Patras, Greece.
Chang-Ki MinDepartment of Blood and Marrow Transplantation, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
Paul CannellDepartment of Medicine, Royal Perth Hospital, Perth, Australia.
Heinz LudwigWilhelminen Cancer Research Institute, Department of Medicine, Center for Oncology, Hematology and Palliative Care, Wilhelminen Hospital, Vienna, Austria.
Pieter SonneveldDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
María Victoria MateosDepartment of Hematology, University Hospital of Salamanca/IBSAL, Salamanca, Spain. mvmateos@usal.es.
PharmaMar (Spain) · ESAlexandra Hospital · GRBarts Health NHS Trust · GBCanberra Hospital · AUCharles University · CZErasmus MC Cancer Institute · NLInstitut Jules Bordet · BEInstituto de Investigación Biomédica de Salamanca · ESInstituto de Investigación Marqués de Valdecilla · ESMater Health Services · AUNational Taiwan University Hospital · TWOspedale Policlinico San Martino · ITParacelsus Medical University · ATRoyal Perth Hospital · AUSeoul St. Mary's Hospital · KRUniversity Hospital Ostrava · CZUniversity of Patras · GRWilhelminen Hospital · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The randomized phase III ADMYRE trial evaluated plitidepsin plus dexamethasone (DXM) versus DXM alone in patients with relapsed/refractory multiple myeloma after at least three but not more than six prior regimens, including at least bortezomib and lenalidomide or thalidomide. Patients were randomly assigned (2:1) to receive plitidepsin 5 mg/m

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBortezomibDepsipeptidesDexamethasoneDisease-Free SurvivalFemaleHumansLenalidomideMaleMiddle AgedMultiple MyelomaPeptides, CyclicSurvival RateBortezomibDepsipeptidesDexamethasoneLenalidomidePeptides, CyclicplitidepsinThalidomideDexamethasoneMultiple myelomaPlitidepsinRefractoryRelapsed

Identifiers

PMID31240472
PMCPMC6700046
OpenAlexW2954467291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.